ML20045F981
| ML20045F981 | |
| Person / Time | |
|---|---|
| Issue date: | 06/16/1993 |
| From: | Rathbun D NRC OFFICE OF CONGRESSIONAL AFFAIRS (OCA) |
| To: | Lehman R, Lieberman J, Sharp P HOUSE OF REP., HOUSE OF REP., ENERGY & COMMERCE, HOUSE OF REP., ENVIRONMENT & PUBLIC WORKS |
| Shared Package | |
| ML20045F982 | List: |
| References | |
| FRN-58FR33396, RULE-PR-30, RULE-PR-32, RULE-PR-35 AD69-1-009, AD69-1-9, CCS, NUDOCS 9307090267 | |
| Download: ML20045F981 (4) | |
Text
j
~
1 f.,
![pa Araq%,
UNITED STATES NUCLE AR REGULATORY COMMISSION g
)_,,c t
WASHINGTON, D. C. 20$55 S,
- /
June 16, 1993 The Honorable Joseph I.
Lieberman, Chairman Subcommittee on Clean Air and Nuclear Regulation Committee on Environment and Public Works United States Senate Washington, D.
C.
20510
Dear Mr. Chairman:
In the near future the Nuclear Regulatory Commission (NRC) intends to publish in the Eederal Reaister the enclosed proposed rule.
This proposed rule would amend the NRC's regulations in 10 CFR Parts 30, 32, and 35 to eliminate certain restrictions regarding the medical use of byproduct material.
Specifically, among other things, the proposed rule would incorporate into NRC's regulations the concept of authorized nuclear pharmacists to allow properly qualified pharmacists greater discretion to prepare radioactive drugs containing ~
byproduct material.
Also, the proposed rule would allow physician authorized users greater discretion to prepare and use radioactive drugs containing byproduct material, the use of byproduct material in research involving human subjects, and the use of radiolabeled biologics containing byproduct material.
The Commission believes that the proposed rule, if adopted, would result in a small cost reduction for medical use licensees without compromising the level of protection of public health and safety against radiological helards.
Sincerely, 7 -)
L,t2.C !
A w
Dennis K.
Rathbun, Director Office of Congressional Affairs
Enclosure:
Federal Register Notice cc:
Senator Alan K.
Simpson I
)
(
02 '
9307090267 930616 PDR PR 0
30 MISC ppg i
s
<a
![yno uq jo,,
UNITED STATES NUCLEAR REGULATORY COMMISSION g
{
t W ASHINGTON, D. C. 20555 June 16, 1993 The Honorable Philip Sharp, Chairman Subcommittee on Energy and Power Committee on Energy and Commerce United States House of Representatives Washington, D.
C.
20515
Dear Mr. Chairman:
In the near future the Nuclear Regulatory Commission (NRC) intends to publish in the Federal Reaister the enclosed proposed rule.
This proposed rule would amend the NRC's regulations in 10 CFR Parts 30, 32, and 35 to eliminate certain restrictions regarding the medical use of byproduct material.
Specifically, among other things, the proposed rule would incorporate into NRC's regulations the concept of authorized nuclear pharmacists to allow properly qualified pharmacists greater discretion to prepare radioactive drugs containing byproduct material.
Also, the proposed rule would allow physician authorized users greater discretion to prepare and use radioactive drugs containing byproduct material, the use of byproduct material in research involving human subjects, and the use of radiolabeled biologics containing byproduct material.
The Commission believes that the proposed rule, if adopted, would result in a small cost reduction for medical use licensees without compromising the level of protection of public health and safety against radiological hazards.
Sincerely, r'
Q vt sut d[I4_-
Dennis K. Rathbun, Director Office of Congressional Affairs
Enclosure:
Federal Regis*er Notice cc:
Rep. Michael Bilirakis i
i I
- g# 0'%q UNITED STATES
[ 'i,,,, %',
NUCLE AR REGULATORY COMMISSION g
g g
WASHINGTON, D. C. 20555 y'
p June 16, 1993 The Honorable Richard Lehman, Chairman Subcommittee on Energy and Mineral Resources Committee on Natural Resources United States House of Representatives Washington, D.
C.
20515
Dear Mr. Chairman:
In the near future the Nuclear Regulatory Commission (NRC) intends to publish in the Federal Recister the enclosed proposed rule.
This proposed rule would amend the NRC's regulations in 10 CFR Parts 30, 32, and 35 to eliminate certain restrictions regarding the medical use of byproduct material.
Specifically, among other things, the proposed rule would incorporate into NRC's regulations the concept of authorized nuclear pharmacists to allow properly qualified pharmacists greater discretion to prepare radioactive drugs containing byproduct material.
Also, the proposed rule would allow physician authorized users greater discretion to prepare and use radioactive drugs containing byproduct material,' the use of byproduct material in research involving human subjects, and the use of radiolabeled biologics containing byproduct material.
The Commission believes that the proposed rule, if adopted, would result in a small cost reduction for medical use licensees without compromising the level of protection of public health and safety against radiological hazards.
Sincerely,
}
' d.,&cbt t
-phuL-Dennis K. Rathbun, Director Office of Congressional Affairs
Enclosure:
Federal Register Notice cc:
Rep. Barbara Vucanovich
i a
l June 16, 1993 The Honorable Richard H. Lehman, Chairman Subcommittee on Energy and Mineral Resources Committee on Natural Resources United States House of Representatives Washington, DC 20515
Dear Mr. Chairman:
In the near future the Nuclear Regulatory Commission (NRC) intends to publish in the Federal Reaister the enclosed proposed rule.
This pro. nosed rule would amend the NRC's regulations in 10 CFR Parts 30, 32, and 35 to eliminate certain restrictions regarding the medical use of byproduct nateriah,without compromising the level of protection of public health and safety against radiological hazards.
Specifically, among other things, the proposed rule would incorpor[te into NRC's regulations the concept of authorized nuclear pharmacists t( allow properly qualified pharmacists greater discretion to prepare radipactive drugs containing byproduct material.
Also, the proposed rule would all,ow physicf an authorized users greater discretion to prepare and use radioactise drugs containing byproduct material, the use of byproduct material in/research involvinghumansubjects,andtheuseofradiolabeledbiologicycontaining byproduct material.
/
/
The Commission believes that the proposed rule, if adopted, would result in a small cost reduction for medical use licenseeste -
Sincerely, Dennis K. Rathbun, Director Office of Congressional Affairs
Enclosure:
Federal Register Notice cc:
Representative Barbara Vucanovich Distribution:
[TSECONG.LET)
Subj-circ-chron Reading Files \\PSBahadur EBeckjord, CHeltemes, BMorris, FCostanzi JTelford, SJones, ATse
- See previous conc.
Offc:RDB:C A:RES DB:DRA:RES RDB:DRA:RES DD:DRA:RES D:DRA:RES DD:GIR:RES Name:ATse: 'w*
Tel ford
- SBahadur*
FCostanzi*
BMorris*
CHeltemes*
Date:l/6/9 1/6/93 1/6/93 1/11/93 1/11/93 1/12/93 Offca -BTR OCA Name:
E c r -
DRathbun Date:
93
/
/93
({ \\
OFFICIAL RECORD COPY
~
i
-.